CSE: VGW OTC: VGWCF CORPORATE PRESENTATION MAY 2019
DISCLAIMER statements. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements and information contained in this Presentation are investigation and due diligence before making an investment. information that a prospective investor may require to fully evaluate an investment in the contemplated transaction. Prospective investors should conduct their own thorough organization, publicly referred to, or disclosed, in whole or in part, without express written permission. This presentation does not purport to be all inclusive or contain all the may not be used or relied upon for any purpose other than as specifically contemplated by a written agreement. The materials may not be circulated outside of the recipient’s could lose all or a substantial amount of his or her investment. This document is not an offer to sell (or solicitation of an offer to buy) any interest in the Company. These materials their investment and who fully understand and are willing to assume the risks involved. An investment may be considered to involve a substantial degree of risk, and an investor This investment is suitable only for sophisticated investors for whom an investment does not constitute a complete investment program, who do not require immediate liquidity for NOTICE TO RECIPIENT applicable securities legislation. Presentation and the Company assumes no obligation to update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by expressly qualified in their entirety by this cautionary statement. The forward-looking statements and information included in this Presentation are made as of the date of this There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such This Presentation contains forward-looking statements and forward-looking information. Often, but not always, forward-looking statements can be identified by the use of words or differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. as of any date subsequent to the date of this Presentation. Although the Company has attempted to identify important factors that could cause actual actions, events or results to products of the Company; competition; and anticipated and unanticipated costs. These forward-looking statements should not be re lied upon as representing the Company’s views necessary financing; the ability to complete a going public transaction; the ability to satisfy the requirements of a stock exchange; the economy generally; consumer interest in the Such forward-looking statements are based on a number of assumptions which may prove to be incorrect, including, but not limited to: the ability of the Company to obtain Actual results and developments are likely to differ, and may differ materially, from those expressed or implied by the forward-looking statements contained in this Presentation. prices; (D) expected growth in the number of users of medical and recreational marijuana anticipated; and (E) the expansion of t he Company’s business into other revenue streams. Company; (B) the intention to grow the business and operations of the Company; (C) anticipated timing for the availability of th e Company’s products to market and expected sale performance or achievements expressed or implied by the forward-looking statements and information. Examples of such statements include: (A) the financial forecast of the and risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, unknown words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be ach ieved. Forward-looking statements involve known and CSE:VGW, OTC:VGWCF 3
CSE:VGW, OTC:VGWCF 4 Our mission is to become the world’s most trusted partner for best-in-class cannabis extraction, testing, formulations and product development.
2016 71% OUR BELIEFS US MAR KET SHAR E ROAD MAP CSE:VGW, OTC:VGWCF 75% 25% 53% 47% 29% “The future of cannabis in Canada is coming, and we are at the forefront.” *Valens forward-looking prediction in the short-term based on market research Source: Cowen Equity Research Report OIL BASED PRODUCTS FLOWER BASED PRODUCTS 2018 FUTURE* – Tyler Robson, CEO THE MARKET IS RAPIDLY MOVING TO OIL BASED PRODUCTS 5
1 2 3 4 EXTRACTION TESTING FORMULATION PRODUCT DEVELOPMENT CSE:VGW, OTC:VGWCF WHAT WE DO VALENS KEY FOCUS AREAS 6
FATS CBN LIPIDS WAXES WHAT IS IT? EXTRACTION CSE:VGW, OTC:VGWCF FATS LIPIDS WAXES CBG 1 THC CBD (DISTILLATE/ISOLATE) OIL REFINEMENT CANNABIS DRIED OIL WINTERIZATION OIL EXTRACTION 7
Valens is the only company providing a wider variety of extraction methods Super/Sub and smell 1 Capsules Tinctures Vapes Edibles Critical CO2 Add back for Ethanol Hydrocarbon Solvent-less Terpene CSE:VGW, OTC:VGWCF EXTRACTION experience, flavour Live Resin allowing us to create more end products and ultimately meeting a larger number of customer needs. Beverages EXTRACTION Capsules Tinctures Vapes Topicals Edibles Hash Others Concentrates Vapes Shatter/Wax Full Spectrum Rosin WHAT IS OUR COMPETITIVE ADVANTAGE? 8
RESIN or HOW WE GENERATE HIGH MARGINS EXTRACTION CSE:VGW, OTC:VGWCF 1 WHITE LABEL INCREASING MARGINS Revenue share Fee for service REFINED OIL Fee for service Fee for service development of oil for market Formulation and product to various refined stages Processing from crude oil flower to crude oil Processing from EXTRACTION 9
A TRUSTED INDUSTRY PARTNER expertise to help ensure we deliver on our EXTRACTION CSE:VGW, OTC:VGWCF …AND MORE 1 GLOBAL INITIATIVES STRATEGIC PARTNERS -Greg Engel, CEO of Organigram and adult recreational cannabis markets. increasing demand of the global medical ongoing commitment to meeting the who can offer the capacity, quality and Trusted by industry-leading producers partnerships with companies like Valens A key element of [our] success is OF MARKET CAP EXTRACTING FOR OVER $45B WORTH EXTRACTION PARTNERS high quality extracts Recognized for our expertise and ability to deliver annual quantities 2 to 4 year renewable contracts with minimum 10 • • •
METALS PESTICIDES TERPENES RESIDUAL SOLVENTS MICROBIALS CANNABINOID PROFILES TESTING Consumer products are built on trust. This starts and ends with reliability and consistency. 2 Global Employees: 70,000 Market Cap: $104B USD Annual Revenue: $24B USD Fisher Scientific. Plant Based Science” by Thermo Named a “Center of Excellence in AND GLOBALLY FOR CANNABIS TESTING VALENS LABS: SETTING STANDARDS DOMESTICALLY testing (required by Health Canada for all producers) Additional revenue source through third-party lab laboratory results world-wide. the cannabis industry to increase the confidence in validated, standardized, and turnkey solutions for Working with Thermo Fisher Scientific to publish fully minimum of 5 days in as little as 24 hours. Valens can perform analyses that typically take a Utilizing the latest state of the art instrumentation, standard for testing laboratories. First ISO 17025 accredited lab - the global gold CSE:VGW, OTC:VGWCF 11
DIFFERENT COMBINATIONS OF MOLECULES CREATE DIFFERENT CONSUMER EXPERIENCES CANNABINOIDS FORMULATIONS CSE:VGW, OTC:VGWCF STEROLS AMIDES PHENOLIC 20+ FLAVONOIDS TERPENES 100+ 140+ 3 ARE PRESENT IN CANNABIS 500+ BIOACTIVE COMPOUNDS Customized flavor introductions emulating characteristics Full spectrum preservation or flower Tasteless, colorless and odorless preference more and more. formulations will drive consumer As the cannabis market matures, custom 12
THE IMPORTANCE OF SECONDARY COMPOUNDS full suite of secondary compounds. FORMULATIONS CSE:VGW, OTC:VGWCF cannabis strain, Pineapple Express * Example of the terpene make-up of the for consumer experience. terpene formulations responsible expertise to create and customize Valens has the capabilities and influenced by terpenes and the effects, which are further receptors to produce different Cannabinoids bind to the body’s 100+ TERPENE FORMULATIONS 3 EXPRESS * PINEAPPLE 13 Alpha Pinene 3%
SORSE EMULSION TECHNOLOGY ONSET FORMULATIONS VALENS’ SOLUTION CURRENT PROBLEMS SHELF STABILITY CONSISTENCY SMELL/TASTE OFFSET WATER SOLUBILITY CSE:VGW, OTC:VGWCF 3 14 • Shelf stable for over 360 days (not proven anywhere else) • Zero cannabis taste, color or odor • Provides effective, consistent dosing • Lower dosage sufficient due to increase in bioavailability when consumed • Faster onset making it the safer and more trusted option. Observed in 5-15 minutes versus normal 30 minutes – 2 hours. • Faster offset making it feel exactly like an alcoholic beverage. Observed in 45 minutes – 2 hours versus normal 4 – 8 hours. • Proprietary formula, exclusive Canadian rights
Recommend
More recommend
